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Suppressive effect of calcium on parathyroid hormone release in
adynamic renal osteodystrophy and secondary hyperparathyroidism. Se-
rum parathyroid hormone (PTH) levels are markedly lower in patients
with the adynamic lesion (AD) of renal osteodystrophy than in those with
secondary hyperparathyroidism (2°HPT), but serum PTH values are often
moderately elevated in AD when compared to subjects with normal renal
and parathyroid gland function (NL). To study the inhibitory effect of
calcium on PTH release in AD and in 2°HPT, the response to two-hour
intravenous calcium infusions was examined in 6 patients with AD, in 31
patients with 2°HPT and in 20 NL. Basal serum PTH levels were 88 51,
536 395, and 26 6 pg/mI, respectively, in AD, 2°HPT and NL, whereas
basal ionized calcium levels did not differ. When expressed as a percentage
of pre-infusion values, PTH levels at the end of two-hour calcium infusions
were higher both in AD (23.2 5.6%) and in 2°HPT (27.8 12.3%) than
in NL, (11.9 5.8%, P < 0.001). Both the amplitude of suppression (%)
and the rate of decline (min') in serum PTH were less in AD and 2°HPT
than in NL, P < 0.05 for each parameter; corresponding values for each
group, with 95% confidence intervals, were 77% (73 to 82) and 0.039
min' (0.030 to 0.048) in AD, 72% (68 to 76) and 0.031 min1 (0.025 to
0.036) in 2°HPT and 87% (84 to 89) and 0.070 min (0.058 to 0.089) in
NL. Neither variable differed between AD and 2°HPT. Basal and nadir
serum PTH levels were highly correlated: r = 0.95 and P < 0.05 in AD; r =
0.90 and P < 0.01 in 2°HPT; r = 0.75 and P < 0.01 in NL. The slope of
this relationship was less, however, both in AD and in 2°HPT than in NL,
P < 0.05 by analysis of co-variance. Thus, serum PTH levels fell below
20% of pre-infusion values in fewer subjects with AD (1 of 6) or 2°HPT (9
of 31) than in NL (17 of 20) ( = 17.81, P < 0.005). The results indicate
that the inhibitory effect of calcium on PTH release in vivo does not differ
in AD and 2°HPT despite marked differences in basal serum PTH levels.
Variations in functional parathyroid gland mass rather than disturbances
in calcium-sensing by the parathyroids probably account not only for the
lower basal serum PTH levels in patients with AD compared to those with
2°HPT, but also for the moderately elevated serum PTH values commonly
seen in patients with AD.
Serum parathyroid hormone (PTH) levels are markedly lower
in patients with the adynamic lesion of renal osteodystrophy than
in those with secondary hyperparathyroidism [1—3]. As such,
parathyroid gland function is often considered to be diminished,
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or suppressed, in this disorder, thereby contributing to the re-
duced rates of bone formation and turnover that characterize
adynamic renal osteodystrophy [3]. When compared to values for
subjects with normal renal function, however, serum PTH levels
remain elevated in many patients, often despite moderate in-
creases in serum calcium concentration [1, 2, 4]. Thus, Hercz et a!
reported that serum PTH levels averaged 66 80 pg/ml in adult
subjects with adynamic renal osteodystrophy and no evidence of
bone aluminum accumulation [3], whereas Salusky et al found
values of 58 52 pg/ml in adolescent patients with adynamic
lesions [1]. Whether disturbances in the regulation of PTH
secretion or modest degrees of parathyroid gland enlargement
account for the persistently high serum PTH levels commonly
seen in patients with the adynamic lesion remains uncertain.
Few studies have evaluated the secretory behavior of the
parathyroid glands in adynamic renal osteodystrophy [5, 6].
Estimates of the set point for calcium-regulated PTH have been
obtained by examining the inverse sigmoidal relationship between
serum ionized calcium and PTH levels over a broad range of
serum calcium concentrations, but this method has yielded con-
flicting results. Thus, Felsenfeld et al reported differences in set
point between patients with adynamic renal osteodystrophy and
those with secondary hyperparathyroidism [6], whereas Sanchez
et al found no change in set point values in either disorder when
compared to subjects with normal renal and parathyroid gland
function [5].
In contrast to this approach, intravenous calcium infusions have
been used by other investigators to study calcium-sensing mech-
anisms in the parathyroid in selected disorders of mineral metab-
olism such as primary hyperparathyroidism and familial hypocal-
ciuric hypercalcemia (FHH) [7], but this technique has not been
used to compare parathyroid gland function in various types of
renal osteodystrophy. To further assess the inhibitory effects of
calcium on PTH release in adynamic renal osteodystrophy, the
response to intravenous calcium infusions was examined in six
patients with adynamic skeletal lesions documented by bone
biopsy who had previously undergone dynamic tests of parathy-
roid gland function [5]. Serum ionized calcium and PTH levels
were measured at frequent and regular intervals during calcium
infusions, and the results were compared to data obtained in 31
patients with bone biopsy-proven secondary hyperparathyroidism
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and 20 volunteer subjects with normal renal and parathyroid gland
function.
Methods
All patients with renal osteodystrophy were clinically stable,
and each underwent an iliac crest bone biopsy after double
tetracycline labeling to establish the histologic subtype of renal
bone disease; the skeletal lesions of renal osteodystrophy were
classified using histomorphometric criteria reported elsewhere
[8]. Six patients had bone biopsy findings of adynamic renal
osteodystrophy, whereas 31 had either mild lesions of secondary
hyperparathyroidism or overt osteitis fibrosa. None of the patients
had evidence of bone aluminum deposition as assessed by histo-
chemical staining, and none were taking aluminum-containing
medications.
Patients with end-stage renal disease were managed by contin-
uous cycling peritoneal dialysis (CCPD) using dialysate containing
3.5 mEq/liter of calcium. The duration of dialysis prior to study
was 27 28 months. The mean age of patients was 15.8 5.1
years, range 9 to 38 years; there were 21 female and 16 male
subjects. All patients had previously been treated with daily oral
doses of calcitriol, hut vitamin D therapy was discontinued for at
least four weeks prior to study.
Twenty volunteer subjects with normal renal function were also
evaluated. The mean age of volunteers was 21 2 years; there
were eleven women and nine men, none of whom had a history of
chronic illness or metabolic bone disease [9].
All assessments of parathyroid gland function were completed
during admissions to the General Clinical Research Center
(GCRC) at UCLA as previously described [9, 10]. Intravenous
infusions of 10% calcium gluconate were done over a two-hour
period to achieve a progressive rise in serum ionized calcium
concentration to a value at least 0.2 mmol/liter above pre-infusion
levels in each subject. Calcium gluconate infusions were begun at
a rate of 2 mg/kg/hr, and the rate of infusion was increased every
20 minutes to a maximum of 8 mg/kg/hr [9, 10]. Blood samples for
measurements of serum ionized calcium and PTH were obtained
30, 15 and 0 minutes before and every 10 minutes during calcium
infusions. The average of the three measurements obtained at 15
minute intervals before starting each infusion was used to deter-
mine the basal serum PTH and ionized calcium value for each
study subject [9, 10].
Serum ionized calcium levels were monitored during calcium
infusions using a calcium-specific electrode (Radiometer ICA-Il,
Copenhagen, Denmark); blood samples were collected anaerobi-
cally, and measurements were obtained immediately thereafter [9,
10]. Serum samples for PTH determinations were separated by
centrifugation immediately after collection, snap frozen on solid
C02, and stored at —70°C. until assay. Ionized calcium levels were
monitored after stopping calcium infusions until values returned
to baseline levels. None of the patients underwent dialysis during
calcium infusions.
All studies were approved by the UCLA Human Subjects
Protection Committee, and written informed consent was ob-
tained from all patients and volunteers.
Biochemical determinations
Serum calcium, ionized calcium, phosphorus, alkaline phospha-
tase, calcitriol and PTH levels in serum were measured using
methods described elsewhere [8—10]. Serum PTH levels were
Table 1. Basal serum ionized calcium and PTH levels in normal
subjects and in patients with two different types renal osteodystrophy
Normal subjects Osteitis fibrosa Adynamic
(N=20) (N=31) (N=6)
Serum PTH pg/mi 26 6 536 395 88 51
Serum ionized calcium 1.23 0.04 1.22 0.07 1.24 0.05
mmol/liter
Serum total calcium 9.0 0.3 9.1 0.5 9.4 0.4
mg/dl
Serum phosphorus 3.6 0.6 6.3 1.2 5.4 0.8
mmoi/iiter
Values are means SD.
determined using an immunoradiometric assay for the intact
(1-84) hormone [11], and serum calcitriol levels were measured by
radioreceptor assay [12].
Statistical analysis
All data are expressed as the mean 1 SD. Comparisons of
mean values among groups were done using analysis of variance
with contrasts [13]. As stated previously, basal serum ionized
calcium and PTH values for each study subject represent the
average of three separate determinations obtained before the
start of calcium gluconate infusions.
Results obtained during calcium infusions were evaluated by
analysis of variance for repeated measures and by paired t-tests
with appropriate correction for multiple comparisons among
groups [13]. To assess the inhibitory effect of increasing serum
ionized calcium concentrations on PTH release, the natural
logarithm (in) of serum PTH levels, expressed as a percentage of
pre-infusion values, was plotted against the serum ionized calcium
concentration at each 10 minute interval during calcium gluconate
infusions at achieve a linear fit of the data as previously described
[7]. Linear regression analysis was done using the method of least
squares [13], and analysis of co-variance was used for comparisons
among three regression relationships [13]. A mono-exponential
curve fitting algorithm of the form y = A et + B was also used
to examine the curvilinear relationship between serum ionized
calcium and PTH levels during intravenous calcium infusions; for
this analysis, results are presented as mean values with 95%
confidence intervals [14].
Results
As expected, basal serum PTH levels differed substantially
among groups (Table 1). Values were markedly elevated in
patients with secondary hyperparathyroidism, whereas serum
PTH levels in patients with adynamic lesions of bone were only
moderately higher than those of subjects with normal renal
function (Table 1). Basal serum ionized calcium levels did not
differ among groups (Table 1).
During intravenous infusions of calcium gluconate, serum
ionized calcium levels rose in each study subject, and the highest
values were seen at the end of two-hour infusions (Fig. 1). The
total increase in serum ionized calcium was less, however, in
patients with secondary hyperparathyroidism (0.23 0.07 mmol/
liter) than in those with adynamic lesions (0.29 0.06 mmol/liter)
or subjects with normal renal function (0.30 0.09 mmol/liter,
P < 0.05), despite identical rates of calcium infusion (Fig. 1).
Serum PTH levels decreased in all subjects during calcium
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gluconate infusions. The maximum reduction in serum PTH was
observed toward the end of the two-hour calcium infusions in both
groups of patients with renal osteodystrophy, whereas serum PTH
levels reached their lowest levels after only 60 to 70 minutes in
those with normal renal and parathyroid gland function (Fig. 2).
The lowest achievable serum PTH level was 28 26 pg/mI in
patients with adynamic bone and 123 96 pg/mi in those with
secondary hyperparathyroidism. Both values exceeded the mini-
mum PTH level attained in subjects with normal renal function
(3 2 pg/ml, P < 0.05; Fig. 2).
When expressed as a percentage of pre-infusion values to adjust
for differences in basal serum PTH levels among groups, serum
PTH levels declined more slowly during calcium infusions in
patients with adynamic renal osteodystrophy and in those with
secondary hyperparathyroidism than in normal subjects (Fig. 3).
At each 10 minute interval, serum PTH levels were greater than
normal in both types of renal osteodystrophy; values did not differ
at any time, however, between patients with adynamic bone and
those with secondary hyperparathyroidism (Fig. 3). Serum PTH
levels at the end of the two-hour calcium infusions were 23.2
5.6% of the pre-infusion values in patients with adynamic renal
osteodystrophy, 27.8 12.3% in those with secondary hyperpara-
thyroidism and 11.9 5.8% of pre-infusion values in subjects with
normal renal function (P < 0.001).
The lowest serum PTH level achieved at the end of two-hour
calcium infusions correlated with the basal serum PTH level in all
three study groups: r = 0.95 and P < 0.05 in patients with
adynamic bone; r = 0.90 and P < 0.01 in those with secondary
hyperparathyroidism; and r = 0.75 and P < 0.01 in subjects with
normal renal function. The relationship between basal and nadir
PTH values differed from normal, however, in both types of renal
osteodystrophy (Fig. 4). The slope of the regression between basal
and nadir PTH values was less both in patients with adynamic
bone and in those with secondary hyperparathyroidism than in
normal subjects, P < 0.05 by analysis of co-variance (Fig. 4). As
such, a smaller proportion of subjects with either adynamic renal
osteodystrophy or secondary hyperparathyroidism demonstrated
a decrease in serum PTH levels to less than 20% of pre-infusion
values ( = 17.81, P < 0.005; Table 2). Despite markedly
different basal serum PTH levels, the slope of the relationship
between basal and nadir serum PTH levels did not differ between
adynamic renal osteodystrophy and secondary hyperparathyroid-
ism (Fig. 4).
The greatest percentage change in serum PTH levels was
observed during the first 45 to 60 minutes of calcium gluconate
infusions in each group of study subjects (Fig. 3). To further assess
the inhibitory effect of calcium on PTH release, the slope of the
relationship between serum ionized calcium and PTH levels over
the initial 60 minutes of calcium infusions was examined by
plotting the natural logarithm of serum PTH levels, expressed as
a percentage of pre-infusion values, against the corresponding
serum ionized calcium concentration at each 10 minute interval
(Fig. 5). Previous work has demonstrated that the slope of this
relationship is reduced in primary hyperparathyroidism and that
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Fig. 3. Serum PTH levels, expressed as a percentage of pre-infusion values,
during iwo-hour calcium infusions in 20 normal subjects (A), in 31 patients
with secondaiy hypeiparathyroidism (•) and in sir patients with adynamic
renal osteodystrophy (LIII). Values are means 1 so.
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Fig. 1. Serum ionized calcium levels during iwo-hour infusions of calcium
gluconate in 20 normal subjects (A), in 31 patients with seconda,y hyper-
parathyroidism (•) and in sir patients with adynamic renal osteodystrophy
(LI). Values are means 1 so.
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Fig. 2. Serum PTH levels during iwo-hour calcium infusions in 31 patients
with seconday hypeiparathyroidism (A, •), in sir patients with adynamic
renal osteodystrophy (B, LI) and in 20 normal subjects (B, A). Values are
means 1 so.
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Fig. 4. The relationship between basal serum PTH values and PTH levels at
the end of two-hour calcium infusions in 20 normal subjects, r = 0.75, P <
0.01 (A, - — - —), in 3lpatients with secondary hyperparathyroidism, r = 0.90,
P < 0.01 (S, - - -) and in six patients with adynamic renal osteodystrophy, r =
0.95, P < 0.05 (LI, —). Note the logarithmic scale for both axes. Slope
values were 1.47, 0.91 and 1.05, respectively, in normal subjects, in patients
with secondary hyperparathyroidism and in those with adynamic lesions,
F = 7.60, P < 0.01 by analysis of co-variance.
Final serum PTH level
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Normal subjects(N = 20)
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Adynamic(N = 6)
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decreases in slope correspond to the size of parathyroid adenomas
[7]. Slope values were lower than normal both in adynamic renal
osteodystrophy and in secondary hyperparathyroidism. There was
no difference in slope, however, between the two types of renal
osteodystrophy (Fig. 5).
These results were confirmed using a mono-exponential curve
fitting algorithm to evaluate the full 120-minute PTH suppression
curve for each group of study subjects. Both the amplitude of
suppression and the rate of decline in serum PTH levels were
reduced in adynamic renal osteodystrophy and secondary hyper-
parathyroidism compared to subjects with normal renal and
parathyroid gland function (Table 3). Neither of these two
variables differed between the two types of renal osteodystrophy
(Table 3).
Discussion
The results of the current study indicate that the inhibitory
effect of calcium on PTH release is both qualitatively and quan-
titatively similar in adynamic renal osteodystrophy and secondary
hyperparathyroidism. Despite marked differences in basal PTH
values, serum PTH levels decreased during two-hour intravenous
calcium infusions in both groups, and the magnitude of the
decline from baseline levels at each ten minute interval did not
differ. Serum PTH levels decreased more rapidly, however, as
serum ionized calcium levels rose in subjects with normal renal
function, and the degree to which serum PTH levels could be
lowered in normal subjects exceeded that of patients with either
adynamic renal osteodystrophy or secondary hyperparathyroid-
Serum ionized calcium, mmoi/lifer
Fig. 5. Serum PTH levels, plotted as the natural logarithm of percent
pre-infusion values, and the con-esponding serum ionized calcium concen-
tration at each 10 minute interval during the initial 60 minutes of calcium
infusions in 20 normal subjects, r —0.93, P < 0.01 (A, - — - —), in 31
patients with secondaty hypetparathyroidism, r = —0.96, P < 0.001 (•, - - -)
and in six patients with adynamic renal osteodystrophy r =
—0.89, P < 0.01
(LI, —). Symbols represent mean values for each group at the designated
sampling interval. Slope values were —12.98, —9.91 and —8.37, respec-
tively, in normal subjects, in patients with secondary hyperparathyroidism
and in those with adynamic lesions, F = 7.47, P < 0.01 by analysis of
co-variance.
ism. Such findings indicate that the inhibition of PTH release by
calcium differs from normal in both types of renal osteodystrophy.
Whether alterations in calcium-sensing mechanisms or variations
in parathyroid gland size account for these findings remains
uncertain [15—18]. In contrast, the ability to detect, or to sense, an
increase in serum ionized calcium and to reduce PTH release as
calcium concentrations rise appears to be functionally equivalent
in secondary hyperparathyroidism and adynamic renal osteodys-
trophy. Accordingly, factors other than disturbances in the regu-
lation of PTH release by calcium are likely to account for the
marked difference in basal serum PTH levels in these two
disorders.
Hyperplasia of the parathyroid glands and alterations in the
regulation of PTH release by calcium are both thought to
contribute to excess PTH secretion in secondary hyperparathy-
roidism, but the relative role of each as modifiers of PTH
secretion in adynamic renal osteodystrophy remains uncertain
[191. Early studies suggested that the set point for calcium-
regulated PTH release differed between subjects with adynamic
renal osteodystrophy and those with secondary hyperparathyroid-
ism [6]. The results of several recent investigations indicate,
however, that the regulation of PTH secretion by calcium does not
differ substantially from normal in either disorder [5, 9]. Because
controversy persists about various methods for evaluating para-
thyroid gland function in vivo in patients with chronic renal
failure, alternative approaches to examining PTH secretion in
chronic renal failure are of considerable interest [20—22]. In this
regard, intravenous infusions of calcium have been used to assess
parathyroid gland function in other clinical disorders such as
familial hypocalciuric hypercalcemia (FHH) and primary hyper-
parathyroidism [7], but comparisons among patients with various
types of renal osteodystrophy have not been done using this
technique.
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Table 2. The number of subjects from each study group in whom
serum PTH levels decreased to less than 20% of pre-infusion values at
the end of two-hour intravenous infusions of calcium gluconate
= 17.81; P < 0.005
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Table 3. The amplitude of suppression and rate of decline in serum PTI-I levels during two-hour intravenous calcium infusions as determined by
mono-exponential curve fit
Normal subjects(N = 20)
Osteitis fibrosa
(N = 31)
Adynamic(N = 6)
Amplitude of suppression % 87 (84—89) 72 (68—76y 77 (73_82)a
Rate of decline min' 0.070 (0.058—0.089) 0.031 (0.025—0.036) 0.039 (0.030_0.048)'
Values are means with 95% confidence intervals.
P < 0.05 vs. normal
In the current study, rather than assessing the full inverse
sigmoidal curve that depicts the relationship between serum
ionized calcium and PTH levels, calcium-sensing by the parathy-
roid glands was evaluated by studying the response to increasing
ionized calcium concentrations during intravenous calcium infu-
sions. The pattern of the decline in serum PTH was quite similar
in adynamic renal osteodystrophy and secondary hyperparathy-
roidism (Fig. 3). Although basal serum PTH levels were markedly
higher in patients with secondary hyperparathyroidism, serum
PTH levels at each 10 minute interval during two-hour calcium
infusions did not differ between the two groups when values were
expressed as a percentage of pre-infusion levels. Values were
greater, however, in both types of renal osteodystrophy than in
subjects with normal renal and parathyroid gland function. Such
findings suggest that the inhibitory effect of calcium on PTH
release is blunted to a similar degree both in adynamic renal
osteodystrophy and in secondary hyperparathyroidism. Although
reductions in the peripheral metabolism of intact 1-84 PTH could
also account for a more gradual decline in serum PTH levels in
both types of renal osteodystrophy, this alteration would not alone
be sufficient to explain measurable increases in the non-suppress-
ible component of PTH release during short-term studies in each
disorder. Thus, serum PTH levels reached their lowest values
during the final portion of the two-hour calcium infusions in all
three study groups, but values did not continue to decline
thereafter.
To further examine the inhibitory effect of calcium on PTH
release in each type of renal osteodystrophy, the natural logarithm
(In) of serum PTH levels, expressed as a percentage of pre-
infusion values, was plotted against the corresponding serum
ionized calcium concentration at each 10 minute interval during
the initial 60 minutes of calcium gluconate infusions. A similar
approach was used by Khosla et alto characterize calcium-sensing
by the parathyroids in patients with FHH, in subjects with primary
hyperparathyroidism and in normal subjects [7]. Because the rate
of calcium infusion in the current investigation exceeded that
employed previously in subjects with normal renal function [7],
only the results obtained during the first 60 minutes of calcium
infusions were used to assess the inhibitory effect of calcium on
PTI-I release. Since most of the reduction in serum PTH levels
occurred during the initial 45 to 60 minutes of each procedure,
this portion of the PTH suppression curve may better reflect the
early response to smaller changes in serum ionized calcium
concentration.
The slope of the regression between serum ionized calcium and
PTH levels during the initial 60 minutes of calcium infusions was
less than normal both in adynamic renal osteodystrophy and in
secondary hyperparathyroidism. There was no difference in slope,
however, between the two subtypes of renal osteodystrophy.
Similar changes were reported in patients with primary hyper-
parathyroidism in whom the magnitude of the reduction in slope
corresponded to the size of parathyroid adenomas. Thus, large
adenomas were associated with low slope values, whereas patients
with small parathyroid tumors had higher slope values that were
quite similar to those of normal subjects [7]. An inverse relation-
ship between slope values and parathyroid gland volume was also
reported by Indridason et al in a smaller number of hemodialysis
patients with secondary hyperparathyroidism in whom the size of
the parathyroid glands was determined by non-invasive imaging
methods [22].
The results obtained using a mono-exponential model to assess
the rate of decline in serum PTH over the full 120-minute course
of calcium gluconate infusions further support these findings [141.
Thus, both the amplitude of suppression and the rate of decline in
serum PTH values were less than normal both in secondary
hyperparathyroidism and adynamic renal osteodystrophy, but
there was no difference in either parameter between the two
disorders. Such findings are consistent with the view that an
increase in parathyroid gland size due to parathyroid gland
hyperplasia contributes substantially to the blunted inhibitory
effect of calcium on PTH release not only in secondary hyper-
parathyroidism, but also in adynamic renal osteodystrophy. In this
regard, basal serum PTH levels in adynamic renal osteodystrophy
often fall within the range of PTI-I values seen in primary
hyperparathyroidism. Thus, although the degree of parathyroid
gland enlargement is several-fold less in primary hyperparathy-
roidism than in secondary hyperparathyroidism, the extent of
parathyroid hyperplasia in adynamic renal osteodystrophy may be
sufficient to modify the intrinsic secretory behavior of the para-
thyroids and to diminish the inhibitory effect of calcium on PTH
release.
No direct measurements of parathyroid gland size were avail-
able for subjects enrolled in the current study, and only two of the
31 patients with secondary hyperparathyroidism subsequently
underwent parathyroidectomy. Although basal serum PTH values
generally reflect the degree of parathyroid gland hyperplasia in
secondary hyperparathyroidism [23], there was no correlation
between basal serum PTH levels and either the percentage
decrease in serum PTH during calcium infusions (r =
—0.19, NS)
or the slope of the linearized ionized calcium-PTH curve (r =
—0,02, NS). Thus, in contrast to primary hyperparathyroidism, the
biochemical severity of secondary hyperparathyroidism did not
appear to modi' the inhibitory effect of calcium on PTH release
as judged by the slope of the relationship between serum ionized
calcium and PTH levels [7]. Additional factors such as the
histologic pattern of parathyroid gland hyperplasia, alterations in
vitamin D receptor expression and/or monoelonal expansion of
subpopulations of parathyroid cells may also influence this rela-
tionship in secondary hyperparathyroidism [24—27].
There was a high degree of correlation between basal serum
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PTH levels and the lowest serum PTH level achieved during
calcium infusions not only in subjects with normal renal function,
but also in those with either adynamic renal osteodystrophy or
secondary hyperparathyroidism (Fig. 4). The slope of this rela-
tionship was reduced, however, in both types of renal osteodys-
trophy. Such changes account for the higher serum PTH levels
observed at the end of calcium infusions in adynamic renal
osteodystrophy and secondary hyperparathyroidism when values
are expressed as a percentage of pre-infusion values. Accordingly,
a smaller proportion of patients with each type of renal osteodys-
trophy experience a reduction in serum PTH levels to values as
low as those of subjects with normal renal and parathyroid gland
function during calcium infusions.
In summary, the response to calcium infusions suggests that the
inhibitory effect of calcium on PTH release in vivo does not differ
in adynamic renal osteodystrophy and secondary hyperparathy-
roidism. Because PTH release from the parathyroid cell persists
even at very high concentrations of ionized calcium, the results of
the current investigation suggest that differences in functional
parathyroid gland mass rather than alterations in calcium-sensing
by the parathyroids are the major determinant of the prevailing
serum PTH level in patients with renal osteodystrophy; a recent
assessment of patients with secondary hyperparathyroidism un-
dergoing regular hemodialysis reached similar conclusions [22].
Although the histologic type of tissue hyperplasia, variations in
vitamin D receptor expression and monoclonal expansion of
subpopulations of parathyroid cells may also contribute, varia-
tions in the degree of parathyroid gland hyperplasia are likely to
account not only for the marked difference in basal serum PTh
levels between adynamic renal osteodystrophy and secondary
hyperparathyroidism, but also for the moderate but persistent
elevations in serum PTH values commonly seen in patients with
adynamic renal osteodystrophy.
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